Exosome technologies
Exosome therapy is a relatively new concept, with both challenges and significant opportunities
Why Exosomes?
Exosomes are nanosized vesicles (50-200nm) released naturally by cells. They are important effectors of cell communication. A key mechanism by which cell therapies work is via release and uptake of exosomes.
Some of the properties of exosomes are:
- they contain unique mix of molecular cargo (including miRNA, proteins, peptides, lipids) that underpin
- their biological effect
- they have homing capabilities that allow them to travel to the site of injury or disease
- their immunomodulatory properties helps normalise the immune system
- being low/non-immunogenic
- they are not rejected by the bodythey have other bioactive properties based on parent cell e.g. angiogenesis, anti-fibrotic, regenerative, etc.
A: Cell
B: Exosome
VivaZome = Nature + Technology
VivaZome is leveraging the best that nature and technology has to offer:
Customised Exosomes
- Cell Source is key; exploit unique cell attributes.
- Multiple cells types screened based on their native biological function.
- Exosome quantity and quality assessed.
- Cell engineering and exosome loading and targeting technologies to enhance function.
- Cell Engineering for immortalisation.
Universal Manufacturing Process
- Optimised, best-in-class technology.
- Proprietary components to complement established technology from leading suppliers.
- Proprietary cells for manufacture.
- Underpinned by extensive characterisation, molecular cargo analysis, potency assays that link attributes to function and clinical targets.
Exosomes as a therapeutic opportunity
Exosome therapy is a relatively new concept, with both challenges and significant opportunities.
VivaZome’s focus:
Novel, scalable processes and technology
Special challenges with large- scale separation and concentration technology and analytics
Opportunities
No registered exosome therapies
Limited but growing clinical experience with exosomes
Challenges
Evolving exosome-specific guidance from regulatory agencies
Growing number of industry players
Sophisticated exosome analytic technology for product specification
Clinical Targets
Retinal Disease Program
- Age-related Macular Degeneration (AMD)
AMD is the leading cause of blindness in the Western World, affecting 18 million Americans, projected to reach 288 million people world-wide by 2040.
Neurological Disease Program
- Traumatic Brain Injury (TBI)
- Post-Traumatic Epilepsy (PTE)
- Degenerative Brain disorders
5.3 million Americans are living with Traumatic Brain Injury at a cost of USD 76.5 billion per annum.
Ischemic Disease Program
- Critical limb ischemia
- Cardiac ischemia
- Cerebral ischemia
Treatment for Critical Limb Ischemia costs >USD 10 billion per annum in USA alone.
